Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia

Dasatinib is currently approved for clinical use as a first-line treatment agent for newly diagnosed chronic myeloid leukemia (CML). However, only a few clinical trials have been performed to evaluate dasatinibinduced PE following first-line therapy. We investigated the incidence and clinical featur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Azuma, Yoshiko, Tsubokura, Yukie, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Ito, Tomoki, Nomura, Shosaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151348/
https://www.ncbi.nlm.nih.gov/pubmed/30283618
http://dx.doi.org/10.4081/hr.2018.7474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151348/
https://www.ncbi.nlm.nih.gov/pubmed/30283618
http://dx.doi.org/10.4081/hr.2018.7474

Ejemplares similares